Turnover: 10.2 million EUR (2019)
Country: France
Cellectis is developing the very first allogeneic immunotherapies based on CAR-T cells, inventing the concept of off-the-shelf ingested CAR-T cells ready for use in the treatment of cancer patients. By capitalizing on its 19 years of expertise in genome engineering, its TALEN ® and the pioneering PulseAgile electroporation technology, Cellectis develops innovative product candidates using the power of the immune system to target and eliminate cancer cells.
Financial Data
DUNS: 428859052
Address: 8 RUE DE LA CROIX JARRY , 75013 PARIS 13
Number of employees: Entre 50 et 99 salariés (2018)
Capital: 2 124 456 EUR
Financial Data:
| Year | Turnover (€) | Net Profit (€) | Fiscal Year End | Fiscal Year Duration |
|---|---|---|---|---|
| 2017 | 26 326 831 EUR | -43 220 689 EUR | 31/12/2017 | 12 |
Company Managers:
| Position | First Name | Last Name | Age | |
|---|---|---|---|---|
| Directeur général | André | Choulika | 59 | |
| Directeur général délégué | David | Sourdive | 57 |
Studies mentioning this company
The gene therapy market - France
Other companies mentioned:
- Sanofi Aventis
- Cellectis
- Généthon
- Gensight Biologics